Compounded Tirzepatide Recall Exposes Sterility Gaps in GLP-1 Supply Chain
Apothecary Pharma recalled compounded tirzepatide for sterility concerns, classified Class II by the FDA, as inspectors documented mold at a Chinese ingredient factory.
Apothecary Pharma Recalls 22 Compounded Tirzepatide Vials Over Sterility Assurance
Apothecary Pharma voluntarily recalled 22 vials of compounded tirzepatide and one NAD+ vial nationwide over a lack of sterility assurance; the FDA classified both as Class II.